414 related articles for article (PubMed ID: 6457135)
21. Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion--a refined index of bone metabolism.
Hyldstrup L; McNair P; Ring P; Henriksen O
Eur J Nucl Med; 1987; 12(12):585-8. PubMed ID: 3107991
[TBL] [Abstract][Full Text] [Related]
22. [Whole-body retention of 99mTc-methylene diphosphonate in skeletal diseases].
Zorn-Bopp E; Büll U; Münzing W; Lang P; Moser EA
Nuklearmedizin; 1983 Feb; 22(1):24-30. PubMed ID: 6223277
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tc-99m MDP, HMDP, and DPD with respect to bone-to-soft tissue ratios.
Buell U; Kirsch CM; Kleinhans E; Jäger B
J Nucl Med; 1983 Dec; 24(12):1201-2. PubMed ID: 6227711
[No Abstract] [Full Text] [Related]
24. Relative lesion detection ability of Tc-99m HMDP and Tc-99m MDP: concise communication.
Van Duzee BF; Schaefer JA; Ball JD; Chilton HM; Cowan RJ; Kuni C; Trow R; Watson NE
J Nucl Med; 1984 Feb; 25(2):166-9. PubMed ID: 6233404
[TBL] [Abstract][Full Text] [Related]
25. Diphosphonates in the evaluation of metabolic bone disease.
Fogelman I; Smith ML
Clin Rheumatol; 1982 Mar; 1(1):41-4. PubMed ID: 6236012
[TBL] [Abstract][Full Text] [Related]
26. A study of the relationship between chemical structure and bone localization of Tc-99m diphosphonic acids: concise communication.
Wang TS; Mojdehi GE; Fawwaz RA; Johnson PM
J Nucl Med; 1979 Oct; 20(10):1066-70. PubMed ID: 536757
[TBL] [Abstract][Full Text] [Related]
27. Skeletal uptake of Tc-99m HEDP in primary hyperparathyroidism.
Fogelman I; Greig WR; Bessent RG; Boyle IT
J Nucl Med; 1977 Oct; 18(10):1040-1. PubMed ID: 409748
[No Abstract] [Full Text] [Related]
28. Technetium-99m MDP vs technetium-99m dicarboxypropane diphosphonate. A clinical comparison in various pathologic conditions.
Godart G; Durez M; Bevilacqua M; Abramovici J; Robience Y
Clin Nucl Med; 1986 Feb; 11(2):92-7. PubMed ID: 3769350
[TBL] [Abstract][Full Text] [Related]
29. [Accumulation of sodium 2,3-dicarboxypropan-1,1-diphosphonate in bone of rabbits (author's transl)].
Nagai K; Otsuka N; Terashima H; Yanagimoto S; Nagase N; Muranaka A; Ito Y
Radioisotopes; 1982 Apr; 31(4):197-8. PubMed ID: 6213983
[No Abstract] [Full Text] [Related]
30. Measurement of 24-hour whole-body retention of Tc-99mMDP with a thyroid uptake probe: quantitative assessment of metabolic and metastatic bone diseases.
Seto H; Futatsuya R; Ihara F; Kamei T; Furumoto N; Ishizaki Y; Hada M; Kakishita M
Radiat Med; 1984; 2(2):87-92. PubMed ID: 6240671
[TBL] [Abstract][Full Text] [Related]
31. [Whole body bone scintigram with 99mTc-HMDP (technetium-99m-hydroxy methylene diphosphonate) (author's transl)].
Isobe Y; Ko S; Umegaki Y; Takahashi S; Kawaguchi N; Wada S; Matsumoto S
Radioisotopes; 1981 Nov; 30(11):606-8. PubMed ID: 7335900
[No Abstract] [Full Text] [Related]
32. [Extraosseous nuclide uptake during skeletal scintigraphy. Heparin-calcium-induced 99mTc-HMDP accumulation].
Baum RP; Brandhorst I; Maul FD; Hör G
Rofo; 1985 Aug; 143(2):247-9. PubMed ID: 2992051
[No Abstract] [Full Text] [Related]
33. Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate.
Smith FW; Gilday DL; Ash JM; Reid RH
Radiology; 1980 Nov; 137(2):501-4. PubMed ID: 6449027
[TBL] [Abstract][Full Text] [Related]
34. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent.
Degrossi OJ; Oliveri P; García del Río H; Labriola R; Artagaveytía D; Degrossi EB
J Nucl Med; 1985 Oct; 26(10):1135-9. PubMed ID: 4045556
[TBL] [Abstract][Full Text] [Related]
35. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication.
Fogelman I; Citrin DL; McKillop JH; Turner JG; Bessent RG; Greig WR
J Nucl Med; 1979 Feb; 20(2):98-101. PubMed ID: 430202
[TBL] [Abstract][Full Text] [Related]
36. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
[TBL] [Abstract][Full Text] [Related]
37. [Local blood flow and bone uptake of methylene-diphosphonate-technetium-99m. 2].
Vattimo A; Martini G
Boll Soc Ital Biol Sper; 1983 Nov; 59(11):1614-7. PubMed ID: 6230088
[No Abstract] [Full Text] [Related]
38. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
39. A clinical comparison of MDP and DMAD.
Rosenthall L; Stern J; Arzoumanian A
Clin Nucl Med; 1982 Sep; 7(9):403-6. PubMed ID: 6214358
[TBL] [Abstract][Full Text] [Related]
40. [Measurement of 24-hr whole-body retention of 99mTc-MDP with a thyroid uptake probe (author's transl)].
Seto H; Kakishita M; Futatsuya R
Radioisotopes; 1981 May; 30(5):263-7. PubMed ID: 6458840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
